Pfizer Japan, Manufacturing and Marketing Authorization for Champix

January 28, 2008 - Pfizer Japan Inc. announced that on January 25, the company received manufacturing and marketing authorization for Champix^® Tablet 0.5 mg/1mg (varenicline tartrate), a smoking cessation aid for smokers dependent on nicotine.

Champix is Japan’s first oral smoking cessation aid developed for smoking cessation treatment. Current ‘Nicotine Replacement Therapy’ relieves withdrawal symptoms associated with smoking cessation by replacing tobacco with nicotine. Champix brings about a smoking cessation effect as a non-nicotine partial agonist¹ that binds to α₄β₂ nicotine receptors in the brain with strong affinity... Pfizer's Press Release-